📣 VC round data is live. Check it out!

Novonesis Valuation Multiples

Discover revenue and EBITDA valuation multiples for Novonesis and similar public comparables like Ningxia Baofeng Energy Group, PPG, Dow, Eternal Ltd and more.

Novonesis Overview

About Novonesis

Novonesis was formed in 2024 through the merger of Novozymes and Chr. Hansen. Following the merger, the company became the world leader in industrial enzymes and microbial solutions, with a nearly 50% market share in both. The firm supplies a wide range of industry groups: household care, food and beverages, bioenergy, agriculture and feed, technical and pharmaceuticals. Its biological solutions create value for its customers by improving yield efficiency and performance, while saving energy and generating less waste. The company is headquartered in Denmark, employs around 10,000 people, and works across more than 30 research and development and application centers and 23 manufacturing sites.


Founded

2000

HQ

Denmark

Employees

11.6K

Financials (LTM)

Revenue: $5B
EBITDA: $2B

EV

$31B

Valuation Multiples

Start free trial

Valuation Multiples for 15K+ Public Comps

AdidasAirbnbAmazonCiscoCoca-ColaDellDropboxIBMIntelMcDonaldsNikeNVIDIASamsungSpotifyTeslaToyota
Browse Valuation Multiples

Novonesis Financials

Novonesis reported last 12-month revenue of $5B and EBITDA of $2B.

In the same LTM period, Novonesis generated $3B in gross profit, $2B in EBITDA, and $758M in net income.

Revenue (LTM)


Novonesis P&L

In the most recent fiscal year, Novonesis reported revenue of $5B and EBITDA of $2B.

Novonesis is profitable as of last fiscal year, with gross margin of 53%, EBITDA margin of 37%, and net margin of 14%.

See analyst estimates for Novonesis
LTMLast FY202320242025202620272028
Revenue$5B$5B$3B$4B$5B
Gross Profit$3B$3B$2B$2B$3B
Gross Margin52%53%54%47%54%
EBITDA$2B$2B$855M$1B$2B
EBITDA Margin37%37%31%27%33%
EBIT Margin24%23%25%17%21%
Net Profit$758M$689M$473M$356M$679M
Net Margin15%14%17%8%14%

Financial data powered by Morningstar, Inc.

Novonesis Stock Performance

Novonesis has current market cap of $27B, and enterprise value of $31B.

Market Cap Evolution


Novonesis' stock price is $58.95.

Novonesis share price decreased by 3.6% in the last 30 days, and by 17.3% in the last year.

Novonesis has an EPS (earnings per share) of $1.48.

See more trading valuation data for Novonesis
EVMarket CapPrice 1DPrice 1MPrice 3MPrice 12MEPS
$31B$27B-0.4%-3.6%-0.6%-17.3%$1.48

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.

Start Free Trial

Novonesis Valuation Multiples

Novonesis trades at 6.2x EV/Revenue multiple, and 16.5x EV/EBITDA.

See NTM and 2027E valuation multiples for Novonesis

EV / Revenue (LTM)


Novonesis Financial Valuation Multiples

As of May 29, 2026, Novonesis has market cap of $27B and EV of $31B.

Novonesis has a P/E ratio of 36.3x.

LTMLast FY202320242025202620272028
EV/Revenue6.2x6.3x11.0x6.9x6.4x
EV/EBITDA16.5x16.9x36.1x25.5x19.1x
EV/EBIT26.0x27.9x44.2x40.2x30.0x
EV/Gross Profit11.9x11.8x20.3x14.6x11.8x
P/E36.3x39.9x58.2x77.2x40.5x
EV/FCF36.1x34.8x94.1x40.2x35.3x

Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Verified Novonesis Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.

FactSetMorningstar
Start Free Trial

Novonesis Margins & Growth Rates

Novonesis grew revenue by 5% and EBITDA by 6% in the last fiscal year.

In the most recent fiscal year, Novonesis reported gross margin of 53%, EBITDA margin of 37%, and net margin of 14%.

See estimated margins and future growth rates for Novonesis

Novonesis Margins

Last FY202420252026202720282029
Gross Margin53%47%54%55%
EBITDA Margin37%27%33%38%
EBIT Margin23%17%21%25%
Net Margin14%8%14%17%
FCF Margin18%17%18%16%

Novonesis Growth Rates

FY+1/FY23/2424/2525/2626/2727/2828/29
Revenue Growth5%59%8%6%
Gross Profit Growth8%39%24%8%
EBITDA Growth6%41%34%20%
EBIT Growth18%10%34%27%
Net Profit Growth25%(25%)91%27%
FCF Growth(9%)134%14%(8%)

Data powered by FactSet, Inc. and Morningstar, Inc.

Novonesis Operational KPIs

Novonesis' revenue per employee in the last FY averaged $0.4M, while opex per employee averaged $0.1M for the same period.

Novonesis' Rule of 40 is 44% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

Novonesis' Rule of X is 53% (created by Bessemer, Rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

Access forward-looking KPIs for Novonesis
LTMLast FY202320242025202620272028
Rule of 4043%44%---
Bessemer Rule of X52%53%---
Revenue per Employee-$0.4M---
Opex per Employee-$0.1M---
S&M Expenses to Revenue17%17%13%14%17%
G&A Expenses to Revenue5%5%5%6%5%
R&D Expenses to Revenue11%11%11%11%11%
Opex to Revenue-32%29%30%33%

Data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 230+ Verticals

Novonesis Competitors

Novonesis competitors include Ningxia Baofeng Energy Group, PPG, Dow, Eternal Ltd, Qinghai Salt Lake Industry, Sika, Bunge, OMV, Muyuan Foods and Givaudan.

Most Novonesis public comparables operate across Agriculture, Chemicals and AgriTech.

EV/RevenueEV/EBITDA
Last FYLTM2027ELast FYLTM2027E
Ningxia Baofeng Energy Group4.3x4.0x12.0x10.6x
PPG2.0x1.9x11.1x11.2x
Dow1.0x1.0x12.5x8.6x
Eternal Ltd4.2x3.7x88.4x134.3x
Qinghai Salt Lake Industry9.0x6.9x17.0x12.4x
Sika2.6x2.6x14.0x13.9x
Bunge0.5x0.5x14.2x12.1x
OMV0.9x0.9x3.5x3.3x

This data is available for Pro users. Sign up to see all Novonesis competitors and their valuation data.

Start Free Trial

Novonesis M&A Activity

Novonesis has acquired 1 company to date.

Last acquisition by Novonesis was on February 11th 2025. Novonesis acquired DSM (feed enzymes unit) for $3B (EV/Revenue multiple of ).

See M&A valuation multiples

Latest Acquisitions by Novonesis

DSM (feed enzymes unit)
Description
-
HQ CountryNetherlands
HQ City
-
Deal Date11 Feb 2025
Valuation$3B
EV/Revenue
EV/EBITDA

This data is available for Pro users. Sign up to see all Novonesis acquisitions and their M&A valuation multiples.

Start Free Trial

Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples

Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.

Start Free Trial

About Novonesis

When was Novonesis founded?Novonesis was founded in 2000.
Where is Novonesis headquartered?Novonesis is headquartered in Denmark.
How many employees does Novonesis have?As of today, Novonesis has over 11K employees.
Who is the CEO of Novonesis?Novonesis' CEO is Ester Baiget.
Is Novonesis publicly listed?Yes, Novonesis is a public company listed on Nasdaq Copenhagen.
What is the stock symbol of Novonesis?Novonesis trades under NSIS B ticker.
When did Novonesis go public?Novonesis went public in 2000.
Who are competitors of Novonesis?Novonesis main competitors include Ningxia Baofeng Energy Group, PPG, Dow, Eternal Ltd, Qinghai Salt Lake Industry, Sika, Bunge, OMV, Muyuan Foods, Givaudan.
What is the current market cap of Novonesis?Novonesis' current market cap is $27B.
What is the current revenue of Novonesis?Novonesis' last 12 months revenue is $5B.
What is the current revenue growth of Novonesis?Novonesis revenue growth (NTM/LTM) is 6%.
What is the current EV/Revenue multiple of Novonesis?Current revenue multiple of Novonesis is 6.2x.
What is the current EBITDA of Novonesis?Novonesis' last 12 months EBITDA is $2B.
What is Novonesis' EBITDA margin?Novonesis' last 12 months EBITDA margin is 37%.
What is the current EV/EBITDA multiple of Novonesis?Current EBITDA multiple of Novonesis is 16.5x.
What is the current FCF of Novonesis?Novonesis' last 12 months FCF is $854M.
What is Novonesis' FCF margin?Novonesis' last 12 months FCF margin is 17%.
What is the current EV/FCF multiple of Novonesis?Current FCF multiple of Novonesis is 36.1x.
How many companies Novonesis has acquired to date?As of May 2026, Novonesis has acquired 1 company.
What was the largest acquisition by Novonesis?$3B acquisition of DSM (feed enzymes unit) on 11th February 2025 was the largest M&A Novonesis has done to date.
What companies Novonesis acquired?Novonesis acquired DSM (feed enzymes unit).
In how many companies Novonesis has invested to date?Novonesis hasn't invested in any companies yet (or none have been disclosed publicly).

See public comps similar to Novonesis

Lists including Novonesis

Start Your
Free Trial Today

Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.

Start Trial